WO2020083311A1 - 作为ret抑制剂的吡嗪衍生物 - Google Patents
作为ret抑制剂的吡嗪衍生物 Download PDFInfo
- Publication number
- WO2020083311A1 WO2020083311A1 PCT/CN2019/112757 CN2019112757W WO2020083311A1 WO 2020083311 A1 WO2020083311 A1 WO 2020083311A1 CN 2019112757 W CN2019112757 W CN 2019112757W WO 2020083311 A1 WO2020083311 A1 WO 2020083311A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- acid
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Definitions
- the invention relates to a compound with a pyrazine structure and its application in the preparation of a medicament for treating diseases related to RET kinase inhibitors. Specifically, it relates to the compound represented by formula (I) and its pharmaceutically acceptable salts.
- RET protein is a receptor tyrosine kinase RTK and a transmembrane glycoprotein. It is expressed by the proto-oncogene RET (REarranged during Transfection) on chromosome 10. It develops during the embryonic stage of the kidney and enteric nervous system. Plays an important role in addition to homeostasis in a variety of tissues, such as neurons, neuroendocrine, hematopoietic tissue, and male germ cells. Unlike other RTKs, RET does not directly bind to ligand molecules: such as artemin, glial cell line-derived neurotrophic factor (GDNF), neuroturin, and persephin, which belong to the GNDF family of ligands (GFLs ).
- ligand molecules such as artemin, glial cell line-derived neurotrophic factor (GDNF), neuroturin, and persephin, which belong to the GNDF family of ligands (GFLs ).
- GFLs usually bind to the GDNF family receptor alpha (GFR ⁇ ), and the formed GFLs-GFR ⁇ complex mediates the self-dimerization of the RET protein, causing trans autophosphorylation of tyrosine on the intracellular domain .
- GFR ⁇ GDNF family receptor alpha
- RET protein GDNF family receptor alpha
- recruit relevant linker proteins, activate cell proliferation and other signaling cascades, and related signaling pathways include MAPK, PI3K, JAK-STAT, PKA, PKC, etc.
- RET carcinogenic activation There are two main mechanisms of RET carcinogenic activation: one is that the rearrangement of chromosomes produces new fusion proteins, usually the fusion of the kinase domain of RET and the protein containing the self-dimerization domain; the second is that the RET mutations are directly or indirectly Activates the kinase activity of RET. These changes in the level of somatic or germ cells are involved in the pathogenesis of various cancers. 5% -10% of patients with papillary thyroid cancer have RET chromosome rearrangement; and 60% of medullary medullary thyroid cancers have RET point mutations; of all NSCLC patients, about 1-2% have RET Fusion proteins, of which KIF5B-RET is the most common.
- RET inhibitors have potential clinical value in tumor or intestinal disorders.
- the present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
- R 1 is selected from H, F, Cl, Br, I and C 1-4 alkyl, the C 1-4 alkyl is optionally substituted by 1, 2 or 3 R;
- R 2 is selected from C 1-4 alkoxy, said C 1-4 alkoxy optionally substituted with 1, 2 or 3 R <
- R 3 is selected from F, Cl, Br, I, and C 1-4 alkyl, the C 1-4 alkyl is optionally substituted with 1, 2, or 3 R;
- R 4 is selected from H, F, Cl, Br, I, OH and NH 2 ;
- R is selected from F, Cl, Br, I, OH, NH 2 and CH 3 ;
- the carbon atom with "*" is a chiral carbon atom and exists in the form of (R) or (S) single enantiomer or enriched in one enantiomer.
- R 1 is selected from CH 3 , CH 2 CH 3 , The CH 3 , CH 2 CH 3 , It can be optionally substituted with 1, 2, or 3 R, and other variables are as defined in the present invention.
- R 1 is selected from CH 3 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , Other variables are as defined in the present invention.
- R 1 is selected from CH 3 , and other variables are as defined in the invention.
- R 2 is selected from Other variables are as defined in the present invention.
- R 3 is selected from CH 3 , CH 2 CH 3 , The CH 3 , CH 2 CH 3 , It can be optionally substituted with 1, 2, or 3 R, and other variables are as defined in the present invention.
- R 3 is selected from CH 3 , CH 2 CH 3 , Other variables are as defined in the present invention.
- R 3 is selected from CH 3 , and other variables are as defined in the invention.
- R 4 is selected from H, F, Cl, Br, and I, and other variables are as defined in the invention.
- the above compound or a pharmaceutically acceptable salt thereof is selected from
- R 1 , R 3 and R 4 are as defined in the present invention.
- the carbon atom with "*" is a chiral carbon atom and exists in the form of (R) or (S) single enantiomer or enriched in one enantiomer.
- the present invention also provides a compound represented by the following formula or a pharmaceutically acceptable salt thereof:
- the above compound or a pharmaceutically acceptable salt thereof is selected from:
- the present invention also provides a pharmaceutical composition, which includes a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.
- the present invention also provides the use of the above compound or a pharmaceutically acceptable salt or composition thereof in the preparation of a RET kinase inhibitor.
- pharmaceutically acceptable refers to those compounds, materials, compositions and / or dosage forms that are within the scope of reliable medical judgment and are suitable for use in contact with human and animal tissues Without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.
- pharmaceutically acceptable salt refers to a salt of a compound of the present invention, prepared from a compound having a specific substituent and a relatively non-toxic acid or base found in the present invention.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Bisulfate, hydroiodic acid, phosphorous acid, etc .; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; similar acids; also includes amino acids (such as arginine, etc.) Salts, and salts of organic acids such as glucuronic acid. Certain compounds of the present invention contain basic and acidic functional groups and can be converted to any base
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing acid radicals or bases by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of appropriate base or acid in water or an organic solvent or a mixture of both.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)-and (+)-enantiomers, (R)-and (S) -enantiomers, diastereomers Isomers, (D) -isomers, (L) -isomers, and their racemic mixtures and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which belong to this Within the scope of the invention. Additional asymmetric carbon atoms may be present in the substituents such as alkyl. All these isomers and their mixtures are included in the scope of the present invention.
- enantiomer or “optical isomer” refers to stereoisomers in a mirror image relationship with each other.
- cis-trans isomer or “geometric isomer” is caused by the fact that double bonds or single bonds of ring-forming carbon atoms cannot rotate freely.
- diastereomer refers to a stereoisomer in which a molecule has two or more chiral centers and there is a non-mirror relationship between the molecules.
- wedge-shaped solid line key And wedge-shaped dotted keys Represents the absolute configuration of a three-dimensional center
- using straight solid line keys And straight dotted keys Represents the relative configuration of the three-dimensional center
- wavy lines Represents a wedge-shaped solid line key Or wedge-shaped dotted key Or with wavy lines Represents a straight solid line key And straight dotted keys
- tautomer or “tautomeric form” means that at room temperature, isomers of different functional groups are in dynamic equilibrium and can quickly convert to each other. If tautomers are possible (as in solution), the chemical equilibrium of tautomers can be achieved.
- proton tautomers also known as prototropic tautomers
- prototropic tautomers include interconversion through proton migration, such as ketone-enol isomerization and imine-enamine Isomerization.
- Valence tautomers include some recombination of bond-forming electrons.
- keto-enol tautomerization is pentane-2,4-dione and Interconversion between two tautomers of 4-hydroxypent-3-en-2-one.
- the terms “rich in one isomer”, “isomer enriched”, “rich in one enantiomer” or “enantiomerically enriched” refer to one of the isomers or pairs
- the content of the enantiomer is less than 100%, and the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or 96% or greater, or 97% or greater, or 98% or greater, or 99% or greater, or 99.5% or greater, or 99.6% or greater, or 99.7% or greater, or 99.8% or greater, or greater or equal 99.9%.
- the terms “isomer excess” or “enantiomeric excess” refer to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the excess of isomer or enantiomer (ee value) is 80% .
- optically active (R)-and (S) -isomers and D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, in which the resulting mixture of diastereomers is separated and the auxiliary group is cleaved to provide pure The desired enantiomer.
- a diastereomeric salt is formed with an appropriate optically active acid or base, and then by conventional methods known in the art The diastereomers are resolved and the pure enantiomers are recovered.
- the separation of enantiomers and diastereomers is usually accomplished by the use of chromatography, which uses a chiral stationary phase, and is optionally combined with chemical derivatization methods (for example, the formation of amino groups from amines) Formate).
- the compound of the present invention may contain unnatural proportions of atomic isotopes in one or more atoms constituting the compound.
- compounds can be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- the hydrogen can be replaced by heavy hydrogen to form a deuterated drug.
- the bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs have lower toxicity and increase drug stability. , Strengthen the efficacy, extend the biological half-life of drugs and other advantages.
- the conversion of all isotopic compositions of the compounds of the present invention, whether radioactive or not, is included within the scope of the present invention.
- substituted means that any one or more hydrogen atoms on a specific atom are replaced by a substituent, which may include heavy hydrogen and hydrogen variants, as long as the valence state of the specific atom is normal and the substituted compound is stable of.
- Oxygen substitution does not occur on aromatic groups.
- optionally substituted means that it may or may not be substituted. Unless otherwise specified, the type and number of substituents may be arbitrary on the basis of chemical realization.
- any variable (such as R) appears more than once in the composition or structure of a compound, its definition in each case is independent.
- R when any variable (such as R) appears more than once in the composition or structure of a compound, its definition in each case is independent.
- the group can optionally be substituted with up to two Rs, and R in each case has independent options.
- combinations of substituents and / or variants thereof are only allowed if such combinations will produce stable compounds.
- linking group When the number of a linking group is 0, such as-(CRR) 0- , it means that the linking group is a single bond.
- one of the variables When one of the variables is selected from a single bond, it means that the two groups to which it is connected are directly connected. For example, when L represents a single bond in A-L-Z, it means that the structure is actually A-Z.
- C 1-4 alkoxy refers to those alkyl groups containing 1 to 4 carbon atoms connected to the rest of the molecule through one oxygen atom.
- the C 1-4 alkoxy group includes C 1- 3 , C 1-2 , C 2-4 , C 4 and C 3 alkoxy groups, and the like.
- C 1-6 alkoxy groups include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy Oxy, s-butoxy and t-butoxy), pentyloxy (including n-pentyloxy, isopentyloxy and neopentyloxy), hexyloxy, etc.
- C 1-4 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 4 carbon atoms.
- the C 1-4 alkyl group includes C 1-2 , C 1-3 and C 2-3 alkyl groups, etc .; it may be monovalent (such as methyl), divalent (such as methylene) or multivalent ( Such as methine).
- Examples of C 1-4 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl , S-butyl and t-butyl) and so on.
- C n-n + m or C n -C n + m includes any specific case of n to n + m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , and also includes any range from n to n + m, for example, C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12, etc .; similarly, n yuan to n + m member means that the number of atoms in the ring is n to n + m, for example, 3-12 member ring includes 3 member ring, 4 member ring, 5 member ring, 6 member ring, 7 member ring, 8 member ring, 9 member ring , 10-membered
- halogen or halogen itself or as part of another substituent means a fluorine, chlorine, bromine or iodine atom.
- leaving group refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (eg, an affinity substitution reaction).
- representative leaving groups include triflate; chlorine, bromine, and iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, and p-toluenesulfonate Ester, etc .; acyloxy, such as acetoxy, trifluoroacetoxy, etc.
- protecting group includes but is not limited to "amino protecting group", “hydroxy protecting group” or “mercapto protecting group”.
- amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
- Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl, or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc) ; Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-methoxyphenyl) methyl; silyl, such as trimethylsilyl (TMS) and tert-butyld
- hydroxyl protecting group refers to a protecting group suitable for preventing side reactions of hydroxyl groups.
- Representative hydroxy protecting groups include but are not limited to: alkyl groups such as methyl, ethyl and tert-butyl; acyl groups such as alkanoyl groups (such as acetyl); arylmethyl groups such as benzyl (Bn), p-methyl Oxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl, such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and so on.
- alkyl groups such as methyl, ethyl and tert-butyl
- acyl groups such as alkanoyl groups (such as acetyl)
- arylmethyl groups such as benzyl (Bn), p-methyl Oxybenzyl (PMB), 9-flu
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by the combination with other chemical synthesis methods, and well known to those skilled in the art Equivalently, preferred embodiments include but are not limited to the embodiments of the present invention.
- the solvent used in the present invention is commercially available.
- the present invention uses the following abbreviations: aq stands for water; eq stands for equivalent and equivalent; M stands for mol / L; DCM stands for dichloromethane; PE stands for petroleum ether; DMF stands for N, N-dimethylformamide; DMSO Stands for dimethyl sulfoxide; EtOAc stands for ethyl acetate; EtOH stands for ethanol; MeOH stands for methanol; rt stands for room temperature; O / N stands for overnight; THF stands for tetrahydrofuran; TFA stands for trifluoroacetic acid; DIPEA stands for diisopropylethylamine; SOCl 2 stands for thionyl chloride; mp stands for melting point.
- the compound of the present invention exhibits good inhibitory activity against wild-type and V804M mutant RET, and will have excellent therapeutic effects in patients with abnormal RET tumors.
- Example 1 Compound 1-A and Compound 1-B
- reaction solution was quenched with water, then extracted with 100 mL of ethyl acetate, extracted three times, and the combined organic phase was added with anhydrous sodium sulfate and dried for half an hour, and then spin-dried to obtain a crude product.
- the crude product was subjected to column chromatography to obtain intermediate 1-02.
- the reaction was heated and stirred at 105 ° C for 3 hours.
- the reaction solution was cooled to room temperature, quenched by adding 20 mL of water, and extracted with 20 mL of ethyl acetate.
- the combined organic phases were extracted three times, dried with anhydrous sodium sulfate for half an hour, and vortexed to obtain a crude product.
- the crude product was purified by column chromatography to obtain intermediate 1-04.
- reaction solution was cooled to room temperature, quenched by adding 20 mL of water, and extracted with 20 mL of ethyl acetate.
- the combined organic phases were extracted three times, dried with anhydrous sodium sulfate for half an hour, and vortexed to obtain a crude product.
- the crude product was purified by column chromatography to obtain intermediate 1-06.
- the compound 1 was sent to a preparative supercritical liquid chromatography for separation and separation method [chromatographic column: DAICEL CHIRALPAK IC (250mm ⁇ 30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water MeOH]; carbon dioxide%: 50% -50%.
- the target compounds 1-A (peak time 5.89 min) and 1-B (peak time 5.10 min) were obtained.
- the 33 P isotope-labeled kinase activity test (Reaction Biology Corp) was used to determine the IC 50 value to evaluate the test compound's ability to inhibit human wild-type, V804M mutant RET.
- Buffer conditions 20 mM hydroxyethylpiperazine ethanesulfonic acid (Hepes) (pH 7.5), 10 mM MgCl 2 , 1 mM ethylene glycol diaminoethyl ether tetraacetic acid (EGTA), 0.02% polyoxyethylene dodecyl ether Brij35), 0.02 mg / mL bovine serum albumin (BSA), 0.1 mM sodium vanadate (Na 3 VO 4 ), 2 mM dithiothreitol (DTT), 1% DMSO.
- Hepes 20 mM hydroxyethylpiperazine ethanesulfonic acid (Hepes) (pH 7.5), 10 mM MgCl 2 , 1 mM ethylene glycol diaminoethyl ether tetraacetic acid (EGTA), 0.02% polyoxyethylene dodecyl ether Brij35), 0.02 mg / mL bo
- test compound treatment The test compound was dissolved in 100% DMSO and serially diluted by Integra Viaflo Assist with DMSO to a specific concentration.
- Test procedure Dissolve the substrate in the newly prepared buffer solution, add the tested kinase to it and mix gently. Using the acoustic technique (Echo 550), the DMSO solution in which the test compound is dissolved is added to the above-mentioned mixed reaction solution, and incubated at room temperature for 20 minutes. The compound concentration in the reaction solution was 3 ⁇ M, 1 ⁇ M, 0.333 ⁇ M, 0.1 ⁇ M, 0.0370 ⁇ M, 0.0123 ⁇ M, 4.12nM, 1.37nM, 0.457nM, 0.152nM. After incubating for 15 minutes, 33 P-ATP (activity 0.01 ⁇ Ci / ⁇ l, Km concentration) was added to start the reaction.
- the kinase activity data is expressed by comparing the kinase activity of the test compound with the kinase activity of the blank group (containing only DMSO).
- the IC 50 value was obtained by curve fitting using Prism4 software (GraphPad).
- the compounds of the present invention exhibit good inhibitory activity against wild-type and V804M mutant RET.
Abstract
Description
Claims (15)
- 根据权利要求3所述化合物或其药学上可接受的盐,其中,R 1选自CH 3。
- 根据权利要求7所述化合物或其药学上可接受的盐,其中,R 3选自CH 3。
- 根据权利要求1~4任意一项所述化合物或其药学上可接受的盐,其中,R 4选自H、F、Cl、Br和I。
- 一种药物组合物,包括治疗有效量的根据权利要求1~12任意一项所述的化合物或其药学上可接受的盐作为活性成分以及药学上可接受的载体。
- 根据权利要求1~12任意一项所述的化合物或其药学上可接受的盐在制备RET激酶抑制剂的应用。
- 根据权利要求13所述的组合物在制备RET激酶抑制剂的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811248585.3 | 2018-10-24 | ||
CN201811248585 | 2018-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020083311A1 true WO2020083311A1 (zh) | 2020-04-30 |
Family
ID=70330932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/112757 WO2020083311A1 (zh) | 2018-10-24 | 2019-10-23 | 作为ret抑制剂的吡嗪衍生物 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020083311A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017161269A1 (en) * | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
CN107250110A (zh) * | 2014-09-10 | 2017-10-13 | 葛兰素史克知识产权发展有限公司 | 作为转染重排(ret)抑制剂的新化合物 |
WO2018017983A1 (en) * | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
-
2019
- 2019-10-23 WO PCT/CN2019/112757 patent/WO2020083311A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107250110A (zh) * | 2014-09-10 | 2017-10-13 | 葛兰素史克知识产权发展有限公司 | 作为转染重排(ret)抑制剂的新化合物 |
WO2017161269A1 (en) * | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
WO2018017983A1 (en) * | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020288567B2 (en) | Pyrrolopyrimidine compound and use thereof | |
WO2022063190A1 (zh) | 吡嗪硫联苯基类化合物及其应用 | |
WO2020259626A1 (zh) | 作为irak4抑制剂的咪唑并吡啶类化合物 | |
WO2020083404A1 (zh) | 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用 | |
WO2021164742A1 (zh) | 喹啉类化合物 | |
JP7374532B2 (ja) | 選択性の高いros1阻害剤としての化合物、及びその使用 | |
WO2021129817A1 (zh) | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 | |
WO2020094084A1 (zh) | 作为ret抑制剂的三并环衍生物 | |
WO2022179578A1 (zh) | 含有亚磺酰基吡啶结构的化合物以及应用 | |
WO2020083311A1 (zh) | 作为ret抑制剂的吡嗪衍生物 | |
WO2020156564A1 (zh) | 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物 | |
WO2021233349A1 (zh) | 吡啶类衍生物及其应用 | |
ES2939506T3 (es) | Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer | |
CN112533903B (zh) | 苯并咪唑衍生物及其作为idh1抑制剂的应用 | |
WO2021164741A1 (zh) | 苯基双酰胺类化合物 | |
WO2020083332A1 (zh) | 作为ret抑制剂的嘧啶衍生物 | |
JP7198386B2 (ja) | Ret阻害剤としての窒素含有スピロ環誘導体 | |
JP7434575B2 (ja) | 重水素化チエノピリジン系化合物 | |
WO2023083200A1 (zh) | 吡唑并环化合物及其应用 | |
WO2022121900A1 (zh) | 吡咯并吡啶类化合物及其应用 | |
WO2022228365A1 (zh) | 六元杂芳并脲环的衍生物及其应用 | |
JP2024510647A (ja) | オキサジアゾール置換スピロ環系化合物とその使用 | |
TW202246279A (zh) | 吡𠯤硫聯苯基類化合物及其應用 | |
WO2020147842A1 (zh) | 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用 | |
WO2022100614A1 (zh) | 苯并脲环衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19875772 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19875772 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19875772 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 18.01.2022 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19875772 Country of ref document: EP Kind code of ref document: A1 |